NovoCure Analyst Ratings
NovoCure's Buy Rating Backed by FDA Approval and Strategic Growth Plans Amidst Potential Risks
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $30
Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)
NovoCure Analyst Ratings
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $30
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $28
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $28
Leerink Partners Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $28
A Quick Look at Today's Ratings for Novocure(NVCR.US), With a Forecast Between $28 to $40
Piper Sandler Reaffirms Their Buy Rating on NovoCure (NVCR)
NovoCure Analyst Ratings
Novocure Upgraded to Buy From Neutral at H.C. Wainwright
Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune's Market Potential
Novocure Is Maintained at In-Line by Evercore ISI Group
NovoCure Analyst Ratings
Evercore Maintains Novocure(NVCR.US) With Hold Rating, Cuts Target Price to $18
Wells Fargo Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $40
Wells Fargo Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $40
Wells Fargo Remains a Buy on NovoCure (NVCR)